Methotrexate and Fatty Liver: Risks and Monitoring

Methotrexate and fatty liver disease are closely linked, and understanding this relationship is important for anyone taking this widely used medicine. Methotrexate, prescribed for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, can cause or worsen hepatic steatosis, fibrosis, and, in some cases, cirrhosis with prolonged use. The risk is greatest in patients who already have fatty liver disease, obesity, type 2 diabetes, or who drink alcohol. This article explains who is most at risk, what monitoring your doctor will arrange, and how to manage your liver health safely during treatment.

Can methotrexate cause or worsen fatty liver disease?

Methotrexate can cause or worsen fatty liver disease, fibrosis, and cirrhosis through hepatocyte accumulation over time, with risk closely linked to cumulative dose and pre-existing liver conditions.

Methotrexate can cause liver damage, including the development or worsening of fatty liver disease (hepatic steatosis), fibrosis, and, in some cases, cirrhosis with prolonged use. This is recognised in the UK methotrexate SmPC and in guidance from the British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD). Methotrexate is a disease-modifying drug used to treat conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

At the doses used to treat inflammatory conditions, methotrexate's anti-inflammatory effects are thought to be largely mediated through adenosine pathways rather than solely through folate inhibition, though it does inhibit dihydrofolate reductase.^[11] The drug accumulates in hepatocytes (liver cells) over time, and this accumulation is associated with progressive liver damage in some patients.

Fatty liver, characterised by excess fat deposited within liver cells, may already be present in patients with conditions such as obesity, type 2 diabetes, or metabolic syndrome. Methotrexate can accelerate or compound this damage. The risk is closely related to cumulative dose, meaning the total amount received over the course of treatment, rather than any single dose.

Not everyone taking methotrexate will develop significant liver problems. NICE and BSR guidance acknowledges this risk and recommends structured monitoring to detect liver changes early. Folic acid supplementation is routinely co-prescribed alongside methotrexate to reduce some of its side effects, though it does not fully protect against hepatotoxicity.^[1][5] Patients should be aware that alcohol significantly increases the risk of liver damage when taking methotrexate. NHS guidance advises avoiding alcohol entirely while taking this medicine.

Who is most at risk of liver problems while taking methotrexate?

Patients with pre-existing fatty liver disease, obesity, type 2 diabetes, heavy alcohol use, renal impairment, or high cumulative methotrexate doses are at greatest risk of significant liver damage.

Patients with pre-existing liver conditions, obesity, type 2 diabetes, or heavy alcohol use are at the highest risk of developing significant liver problems while taking methotrexate. These factors can independently cause fatty liver disease, and when combined with methotrexate's hepatotoxic effects, the risk of fibrosis or cirrhosis is substantially increased.

Specific risk factors identified in UK clinical guidance include:

• Pre-existing liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD, previously called NAFLD) or steatohepatitis

• Obesity (body mass index above 30 kg/m²)

• Type 2 diabetes mellitus and insulin resistance

• Excessive alcohol consumption, even at levels below those causing obvious harm

• High cumulative methotrexate dose: historically, a total lifetime dose above 1.5 g was used as a trigger for liver biopsy, particularly in psoriasis. Current BSR and BAD guidance has moved away from this as a fixed threshold, favouring non-invasive fibrosis assessment throughout treatment rather than a single cumulative dose trigger^[10]

• Renal impairment, which reduces methotrexate clearance and increases tissue exposure

• Concomitant use of medicines that interact with methotrexate or are independently hepatotoxic: trimethoprim and co-trimoxazole are particularly important as they can increase methotrexate toxicity by reducing its renal clearance; isoniazid is an example of a medicine with independent hepatotoxic potential.^[1][2] NSAIDs may also reduce methotrexate clearance and increase toxicity risk, though their primary concern in this context is pharmacokinetic rather than direct liver toxicity

• Older age and a longer duration of treatment

Patients with psoriasis appear to carry a somewhat higher baseline risk of liver damage from methotrexate compared with those treated for rheumatoid arthritis, possibly because psoriasis itself is associated with metabolic syndrome and fatty liver disease.^[1] Clinicians should conduct a thorough baseline assessment of all these risk factors before initiating treatment, and patients should be honest about their alcohol intake and any existing health conditions, as this directly influences monitoring frequency and treatment decisions.

What monitoring and tests will my doctor arrange?

Doctors arrange regular liver function tests, initially every one to two weeks then every two to three months once stable, with ELF testing or FibroScan used to assess fibrosis in higher-risk patients.

Your doctor will arrange regular blood tests to monitor your liver function throughout methotrexate treatment, in line with BSR, BAD, and Specialist Pharmacy Service (SPS) guidance. Before starting methotrexate, a baseline assessment typically includes liver function tests (LFTs), a full blood count, renal function tests, and, where clinically indicated by risk factors or local protocol, hepatitis B and C serology, as viral hepatitis can be reactivated or worsened by immunosuppressive therapy. Whether hepatitis screening is performed routinely or on a risk-stratified basis varies by specialty and local protocol.

Once treatment begins, liver function tests are usually checked every one to two weeks initially, then monthly once the dose is stable, and every two to three months thereafter if results remain consistently normal, in line with SPS and BSR monitoring schedules.^[9][4] Particular attention is paid to levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are markers of liver cell injury. A persistent rise above two times the upper limit of normal typically prompts a dose reduction or treatment pause; a rise above three times the upper limit of normal usually leads to stopping the drug and seeking specialist advice, in line with UK guidance.^[9][1]

For patients at higher risk of liver fibrosis, or where blood tests suggest ongoing liver injury, further investigation may be arranged. This can include:

• Enhanced liver fibrosis (ELF) blood test, a non-invasive panel that estimates the degree of liver scarring

• FibroScan (transient elastography), an ultrasound-based technique that measures liver stiffness as a surrogate for fibrosis

• Liver biopsy, now less commonly performed than in previous decades but still used in selected cases where non-invasive tests are inconclusive or discordant

The shift towards non-invasive monitoring has been significant in recent years. Current BSR and BAD guidance favours ELF testing and FibroScan as first-line investigations for fibrosis assessment, reserving biopsy for cases where results are borderline or discordant.^[10]

Managing fatty liver safely if you need methotrexate treatment

Fatty liver does not automatically prevent methotrexate use, but requires avoiding alcohol, optimising weight and metabolic control, taking folic acid as prescribed, and using the lowest effective dose.

Fatty liver disease does not automatically prevent someone from taking methotrexate, but it does require careful management and closer monitoring to minimise the risk of progressive liver damage. The most important steps involve addressing modifiable risk factors alongside the drug treatment itself.

Lifestyle measures play a central role and include:

• Avoiding alcohol entirely, as NHS guidance advises for patients taking methotrexate, given the substantially increased hepatotoxicity risk

• Achieving and maintaining a healthy weight: NICE guidance on non-alcoholic fatty liver disease (NICE NG49) supports weight loss of around 5 to 10 per cent of body weight as a target that can meaningfully reduce liver fat and inflammation^[7]

• Managing blood glucose and lipid levels in patients with type 2 diabetes or metabolic syndrome, as good metabolic control reduces the burden on the liver

• Taking folic acid as prescribed: a common UK regimen is 5 mg once weekly on a non-methotrexate day, though regimens vary between clinics and should be followed as individually prescribed. Folic acid reduces some side effects but does not eliminate liver risk

From a prescribing perspective, clinicians may consider using the lowest effective dose of methotrexate, reviewing the need for concomitant medicines that interact with methotrexate (including trimethoprim, co-trimoxazole, and NSAIDs, which can affect methotrexate clearance), and ensuring renal function is optimised. In some patients, the balance of benefit and risk may lead to a discussion about alternative treatments.

Patients who require ongoing methotrexate for a condition such as rheumatoid arthritis or psoriasis should not stop treatment without speaking to their specialist, as uncontrolled disease also carries significant health risks. The goal is to continue effective treatment while protecting the liver through monitoring, lifestyle change, and dose optimisation.

When should I speak to my doctor about my liver health?

Contact your GP promptly if you develop jaundice, dark urine, persistent nausea, abdominal pain, unusual fatigue, or easy bruising, as these may indicate significant liver damage requiring urgent assessment.

You should contact your GP or specialist promptly if you develop any new symptoms that could suggest liver problems while taking methotrexate. Although early liver damage is often silent and detected only through blood tests, more advanced liver disease can produce noticeable symptoms that require timely assessment.

Contact your GP if you notice any of the following:

• Persistent nausea, loss of appetite, or unexplained weight loss

• Abdominal discomfort or pain, particularly in the upper right side of the abdomen

• Yellowing of the skin or whites of the eyes (jaundice)

• Dark urine or pale stools, which can indicate impaired bile flow

• Unusual fatigue or weakness that is new or worsening

• Easy bruising or bleeding, which may suggest reduced liver synthetic function

If you experience severe abdominal pain, vomiting blood, or sudden confusion, these are potentially serious symptoms requiring urgent assessment. In such cases, call 999 or go to your nearest accident and emergency department immediately. For urgent advice that does not require an emergency response, NHS 111 is available around the clock.

You should also speak to your doctor if your circumstances change in ways that affect your liver risk, for example if you are diagnosed with type 2 diabetes, gain significant weight, or begin taking a new medication that may interact with methotrexate.

It is important to be aware that methotrexate is contraindicated in pregnancy and during breastfeeding. Effective contraception is required for both men and women during treatment and for a period after stopping, as specified in the UK SmPC. If you are planning a pregnancy or think you may be pregnant, contact your doctor immediately before taking any further doses.

Never stop methotrexate suddenly without medical advice, as this can cause a flare of your underlying condition.

If you experience a side effect you believe is related to methotrexate, you or your healthcare professional can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the national evidence base on drug safety.

Scientific References

1. Methotrexate 2.5 mg Tablets – Summary of Product Characteristics.
2. Methotrexate 25 mg/ml Injection – Summary of Product Characteristics.
3. Nordimet (Methotrexate) – EPAR Product Information.
4. Side effects of methotrexate.
5. How and when to take methotrexate.
6. Pregnancy, breastfeeding and fertility while taking methotrexate.
7. Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD): assessment and management. Guideline NG49.
8. Rheumatoid arthritis in adults: management. Guideline NG100.
9. Methotrexate – drug monograph. BNF/NICE.
10. LIVERFASt for assessing and monitoring liver fibrosis and steatosis – MIB317.
11. Cronstein BN. The antiinflammatory mechanism of methotrexate. Arthritis & Rheumatism. 1993. PMID 8254024.
12. Stone SR et al. Inhibition of dihydrofolate reductase from bacterial and vertebrate sources by methotrexate and 5-deazamethotrexate. Biochemistry. 1984. PMID 6367748.

Frequently Asked Questions